Last update Aug. 30, 2018
First generation antihistamine (H1) of the ethanolamine type, with an anticholinergic activity and sedative effects, used in the treatment of allergic disorders.
It is a common component of medications for the symptomatic relief of the common cold (FDA 2013).
Its use is unauthorized in children under 2 years old.
Administered orally every 12 hours.
Since the last update we have not found published data on its excretion in breastmilk and the lack of available pharmacokinetic data makes it impossible to predict it.
There is very little literature in relation to this medication.
In the immediate postpartum, an inhibitory effect on the secretion of prolactin has been observed, which, however, does not influence the stimulation produced by the baby’s sucking (Messinis 1985).
There is a possibility of drowsiness with the use of high doses (Ito 1993, Chow 2015).
If used while breastfeeding, it is advisable to monitor drowsiness and the adequate feeding of the infant.
It is not recommended to share a bed with the baby if this medication is being taken (UNICEF 2013, Landa 2012, ABM 2008, UNICEF 2006).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.